Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX Treatment of Masseter Muscle Prominence
NCT04073303Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2019
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in masseteric hypertrophy (MH) comparing BOTOX with Placebo (2 arms). Primary endpoint: Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90. Started Aug 2019; status: completed.
02
Drugs
botulinum toxin
03
Conditions
masseteric hypertrophy (MH)
Beyond the preview
Go deeper on NCT04073303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073303.